Building Gene Therapy Commercial Readiness From Day One
Navigating the pathway from early discovery to commercial approval in cell and gene therapy requires foresight, rigor, and proactive alignment. In this presentation, Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, outlines what it takes to take a gene therapy program from initial development to commercial readiness and AAV commercial manufacturing readiness.
Learn how building gene therapy commercial readiness from day one helps biopharma innovators de-risk development, streamline Process Performance Qualification (PPQ), and establish a seamless pathway toward BLA submission and commercial manufacturing. Drawing on real-world milestones, including Andelyn’s manufacturing role in Ultragenyx’s FDA-approved therapy, this session breaks down the critical pillars needed for clinical and commercial success and shows how GMP-ready gene therapy manufacturing and a strong gene therapy CDMO partnership enable scale-up and launch. It also clarifies what commercial readiness means for gene therapy products, how commercial readiness is assessed for gene therapies, the main barriers to commercial readiness in gene therapy, how long it can take to reach commercial readiness, and which regulatory milestones indicate commercial readiness for gene therapies.
What commercial readiness means and how it is assessed
For gene therapy products, commercial readiness means the program has achieved robust process characterization, validated analytical methods, consistent quality and yield at commercial scale, AAV commercial manufacturing readiness, and the organizational systems to sustain supply post-approval. Assessment of gene therapy commercial readiness includes end-to-end reviews of process and product understanding, PPQ planning and execution, facility and equipment qualification, supply chain assurance, and data packages that support BLA/MAA filings. Sponsors and a CDMO partnership for gene therapy jointly evaluate GMP readiness for gene therapy manufacturing via risk assessments, comparability plans, stability data, and inspection preparedness. Independent quality audits, mock inspections, and governance checkpoints also confirm commercial and GMP readiness for gene therapy manufacturing.
Main barriers, timelines, and regulatory milestones
The main barriers to commercial readiness in gene therapy include gaps in late-stage analytics, potency assay variability, vector yield and impurity control, tech transfer misalignment, raw material variability, and incomplete validation packages. Regulatory expectations for viral safety, adventitious agent testing, and control of empty/full ratios can also slow AAV commercial manufacturing readiness. Timelines vary, but moving from Phase 1/2 to full gene therapy commercial readiness often takes 18–36 months, depending on data maturity, CMC complexity, and how early a CDMO partnership for gene therapy is established. Key regulatory milestones that indicate commercial readiness for gene therapies include successful completion of process characterization, readiness for and execution of PPQ, pre-license inspection (PLI) or pre-approval inspection (PAI) readiness, acceptance of the BLA/MAA for review, and resolution of major CMC review items. Together, these milestones signal that the program is approaching gene therapy commercial readiness and sustained GMP readiness gene therapy manufacturing.
Key Discussion Topics
- Early-stage process development and how early data collection directly feeds late-stage regulatory and manufacturing validation to support AAV commercial manufacturing readiness.
- Navigating the path to PPQ, encompassing product and process understanding, risk assessments, and facility characterization that underpin gene therapy commercial readiness.
- Five critical focus areas for commercial readiness: process characterization, analytical methods readiness, GMP inspection readiness, PPQ execution, and sponsor-CDMO alignment, each essential to GMP readiness gene therapy manufacturing.
- Real-world insights and case studies demonstrating how strong collaboration between sponsor and CDMO accelerates advanced therapies to market through a high-functioning CDMO partnership for gene therapy.
Navigating the pathway from early discovery to commercial approval in cell and gene therapy requires foresight, rigor, and proactive alignment. In this presentation, Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, outlines what it takes to take a gene therapy program from initial development to commercial readiness and AAV commercial manufacturing readiness.
Learn how building gene therapy commercial readiness from day one helps biopharma innovators de-risk development, streamline Process Performance Qualification (PPQ), and establish a seamless pathway toward BLA submission and commercial manufacturing. Drawing on real-world milestones, including Andelyn’s manufacturing role in Ultragenyx’s FDA-approved therapy, this session breaks down the critical pillars needed for clinical and commercial success and shows how GMP-ready gene therapy manufacturing and a strong gene therapy CDMO partnership enable scale-up and launch. It also clarifies what commercial readiness means for gene therapy products, how commercial readiness is assessed for gene therapies, the main barriers to commercial readiness in gene therapy, how long it can take to reach commercial readiness, and which regulatory milestones indicate commercial readiness for gene therapies.
What commercial readiness means and how it is assessed
For gene therapy products, commercial readiness means the program has achieved robust process characterization, validated analytical methods, consistent quality and yield at commercial scale, AAV commercial manufacturing readiness, and the organizational systems to sustain supply post-approval. Assessment of gene therapy commercial readiness includes end-to-end reviews of process and product understanding, PPQ planning and execution, facility and equipment qualification, supply chain assurance, and data packages that support BLA/MAA filings. Sponsors and a CDMO partnership for gene therapy jointly evaluate GMP readiness for gene therapy manufacturing via risk assessments, comparability plans, stability data, and inspection preparedness. Independent quality audits, mock inspections, and governance checkpoints also confirm commercial and GMP readiness for gene therapy manufacturing.
Main barriers, timelines, and regulatory milestones
The main barriers to commercial readiness in gene therapy include gaps in late-stage analytics, potency assay variability, vector yield and impurity control, tech transfer misalignment, raw material variability, and incomplete validation packages. Regulatory expectations for viral safety, adventitious agent testing, and control of empty/full ratios can also slow AAV commercial manufacturing readiness. Timelines vary, but moving from Phase 1/2 to full gene therapy commercial readiness often takes 18–36 months, depending on data maturity, CMC complexity, and how early a CDMO partnership for gene therapy is established. Key regulatory milestones that indicate commercial readiness for gene therapies include successful completion of process characterization, readiness for and execution of PPQ, pre-license inspection (PLI) or pre-approval inspection (PAI) readiness, acceptance of the BLA/MAA for review, and resolution of major CMC review items. Together, these milestones signal that the program is approaching gene therapy commercial readiness and sustained GMP readiness gene therapy manufacturing.
Key Discussion Topics
- Early-stage process development and how early data collection directly feeds late-stage regulatory and manufacturing validation to support AAV commercial manufacturing readiness.
- Navigating the path to PPQ, encompassing product and process understanding, risk assessments, and facility characterization that underpin gene therapy commercial readiness.
- Five critical focus areas for commercial readiness: process characterization, analytical methods readiness, GMP inspection readiness, PPQ execution, and sponsor-CDMO alignment, each essential to GMP readiness gene therapy manufacturing.
- Real-world insights and case studies demonstrating how strong collaboration between sponsor and CDMO accelerates advanced therapies to market through a high-functioning CDMO partnership for gene therapy.
Navigating the pathway from early discovery to commercial approval in cell and gene therapy requires foresight, rigor, and proactive alignment. In this presentation, Matt Niloff, Chief Commercial Officer at Andelyn Biosciences, outlines what it takes to take a gene therapy program from initial development to commercial readiness and AAV commercial manufacturing readiness.
Learn how building gene therapy commercial readiness from day one helps biopharma innovators de-risk development, streamline Process Performance Qualification (PPQ), and establish a seamless pathway toward BLA submission and commercial manufacturing. Drawing on real-world milestones, including Andelyn’s manufacturing role in Ultragenyx’s FDA-approved therapy, this session breaks down the critical pillars needed for clinical and commercial success and shows how GMP-ready gene therapy manufacturing and a strong gene therapy CDMO partnership enable scale-up and launch. It also clarifies what commercial readiness means for gene therapy products, how commercial readiness is assessed for gene therapies, the main barriers to commercial readiness in gene therapy, how long it can take to reach commercial readiness, and which regulatory milestones indicate commercial readiness for gene therapies.
What commercial readiness means and how it is assessed
For gene therapy products, commercial readiness means the program has achieved robust process characterization, validated analytical methods, consistent quality and yield at commercial scale, AAV commercial manufacturing readiness, and the organizational systems to sustain supply post-approval. Assessment of gene therapy commercial readiness includes end-to-end reviews of process and product understanding, PPQ planning and execution, facility and equipment qualification, supply chain assurance, and data packages that support BLA/MAA filings. Sponsors and a CDMO partnership for gene therapy jointly evaluate GMP readiness for gene therapy manufacturing via risk assessments, comparability plans, stability data, and inspection preparedness. Independent quality audits, mock inspections, and governance checkpoints also confirm commercial and GMP readiness for gene therapy manufacturing.
Main barriers, timelines, and regulatory milestones
The main barriers to commercial readiness in gene therapy include gaps in late-stage analytics, potency assay variability, vector yield and impurity control, tech transfer misalignment, raw material variability, and incomplete validation packages. Regulatory expectations for viral safety, adventitious agent testing, and control of empty/full ratios can also slow AAV commercial manufacturing readiness. Timelines vary, but moving from Phase 1/2 to full gene therapy commercial readiness often takes 18–36 months, depending on data maturity, CMC complexity, and how early a CDMO partnership for gene therapy is established. Key regulatory milestones that indicate commercial readiness for gene therapies include successful completion of process characterization, readiness for and execution of PPQ, pre-license inspection (PLI) or pre-approval inspection (PAI) readiness, acceptance of the BLA/MAA for review, and resolution of major CMC review items. Together, these milestones signal that the program is approaching gene therapy commercial readiness and sustained GMP readiness gene therapy manufacturing.
Key Discussion Topics
- Early-stage process development and how early data collection directly feeds late-stage regulatory and manufacturing validation to support AAV commercial manufacturing readiness.
- Navigating the path to PPQ, encompassing product and process understanding, risk assessments, and facility characterization that underpin gene therapy commercial readiness.
- Five critical focus areas for commercial readiness: process characterization, analytical methods readiness, GMP inspection readiness, PPQ execution, and sponsor-CDMO alignment, each essential to GMP readiness gene therapy manufacturing.
- Real-world insights and case studies demonstrating how strong collaboration between sponsor and CDMO accelerates advanced therapies to market through a high-functioning CDMO partnership for gene therapy.